

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property  
Organization  
International Bureau



(43) International Publication Date  
10 March 2005 (10.03.2005)

PCT

(10) International Publication Number  
WO 2005/021594 A3

(51) International Patent Classification<sup>7</sup>: C07K 16/30,  
16/46, A61K 39/395, A61P 35/00, G01N 33/574, 33/577,  
A61K 51/10, C12N 15/13, 15/62, 5/10, 15/79

(21) International Application Number:  
PCT/US2004/028004

(22) International Filing Date: 27 August 2004 (27.08.2004)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:  
60/498,903 29 August 2003 (29.08.2003) US

(71) Applicant (for all designated States except US): THE  
GOVERNMENT OF THE UNITED STATES OF  
AMERICA, as represented by THE SECRETARY OF  
THE DEPARTMENT OF HEALTH AND HUMAN  
SERVICES [US/US]; National Institutes of Health, Office  
of Technology Transfer, 6011 Executive Boulevard, Suite  
325, Rockville, MD 20852-3804 (US).

(72) Inventors; and

(75) Inventors/Applicants (for US only): KASHMIRI, Syed,  
V., S. [US/US]; 11541 Brandy Hall Lane, Gaithersburg,  
MD 20878 (US). SCHLOM, Jeffrey [US/US]; 10301 Sor-  
rel Avenue, Potomac, MD 20854 (US). PADLAN, Ed-  
uardo, A. [US/US]; 4006 Simms Drive, Kinsington, MD  
20895 (US).

(74) Agent: CARLSON, Anne; Klarquist Sparkman, LLP, One  
World Trade Center, Suite 1600, 121 SW Salmon Street,  
Portland, OR 97204 (US).

(81) Designated States (unless otherwise indicated, for every  
kind of national protection available): AE, AG, AL, AM,

AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN,  
CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI,  
GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE,  
KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD,  
MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG,  
PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM,  
TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM,  
ZW.

(84) Designated States (unless otherwise indicated, for every  
kind of regional protection available): ARIPO (BW, GH,  
GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM,  
ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM),  
European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI,  
FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI,  
SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ,  
GW, ML, MR, NE, SN, TD, TG).

Declaration under Rule 4.17:

— of inventorship (Rule 4.17(iv)) for US only

Published:

- with international search report
- before the expiration of the time limit for amending the  
claims and to be republished in the event of receipt of  
amendments
- with (an) indication(s) in relation to deposited biological  
material furnished under Rule 13bis separately from the  
description
- with sequence listing part of description published sepa-  
rately in electronic form and available upon request from  
the International Bureau

(88) Date of publication of the international search report:  
16 June 2005

For two-letter codes and other abbreviations, refer to the "Guid-  
ance Notes on Codes and Abbreviations" appearing at the begin-  
ning of each regular issue of the PCT Gazette.

(54) Title: MINIMALLY IMMUNOGENIC VARIANTS OF SDR-GRAFTED HUMANIZED ANTIBODY CC49 AND THEIR  
USE

(57) Abstract: Humanized anti-TAG-72 CC49 monoclonal antibodies are disclosed herein. The antibodies include a light chain Complementarity Determining Region (L-CDR)1, a L-CDR2, and a L-CDR3; and a heavy chain Complementarity Determining Region (H-CDR)1, a H-CDR2, and a H-CDR3 from humanized antibody HuCC49V10. The L-CDR1, L-CDR2, L-CDR3 are within a HuCC49V10 light chain framework region that includes the corresponding amino acid from LEN at position 5, 19, 21, and 106 in the light chain. The H-CDR1, H-CDR2, and H-CDR3 are within a heavy chain HuCC49V10 framework comprising a human 21/28' CL residue at positions 20, 38, 48, 66, 67, 69, and 80 in the heavy chain. These humanized CC49 antibodies retain binding affinity for TAG-72 and have reduced immunogenicity, as compared to a parental HuCC49V10 antibody. Methods are disclosed herein for using these antibodies in the treatment or diagnosis of a tumor, such as a carcinoma, expressing TAG-72.



WO 2005/021594 A3